Akebia Therapeutics, Inc. AKBA 深 沪
等待开盘 05-12 09:30:00 美东时间
1.185
+0.025
+2.16%
华盛通- 最 高1.53
- 今 开1.15
- 成交量 345.21万股
- 最 低 1.125
- 昨 收 1.16
- 总市值 21.80万
- 52周最高 4.0787
- 市盈率 静 --
- 换手率 1876.16%
- 52周最低 1.125
- 委 比 56.03%
- 总股本 0.00亿
- 历史最高 31.00
- 量 比 0.84
- 振 幅 34.91%
- 历史最低 0.241
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.
2025-12-01 22:43
Market-Moving News for December 1st
QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% | Dyadic
2025-12-01 20:37
Akebia Therapeutics Q3 Sales $58.766M Beat $58.235M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $58.766 million which beat the analyst consensus estimate of $58.235 million by 0.91 percent. This is a 57.01 percent increase over sales of $37.428 million
2025-11-10 20:04
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
Akebia Therapeutics announces the publication of vadadustat clinical data in JASN, showing similar safety and efficacy in U.S. and non-U.S. patients with CKD-related anemia, with higher MACE risk in non-U.S. NDD-CKD patients.
2025-06-04 12:00
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Akebia Therapeutics granted stock options to purchase 137,000 shares to three new employees on May 30, 2025, as an inducement for their employment. The options have an exercise price of $3.03 per share, vesting over four years, and expire in 10 years.</p>
2025-06-02 20:05
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
Akebia Therapeutics executives will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:45 AM EDT. A webcast will be available on Akebia’s website following the event. The conference takes place June 3-5 in New York City.
2025-05-28 12:00
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
Akebia Therapeutics will present clinical data on vadadustat at the 62nd European Renal Association Congress in Vienna on June 4-7, 2025. The presentations include studies on cardiovascular safety, combination with ferric citrate, and real-world use in Japan.
2025-05-27 12:00
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $7.5 price target.
2024-09-06 19:27
